The FDA has granted priority review to giredestrant for the treatment of er-positive early breast cancer. The drug, developed by roche, is an oral serd with positive phase iii results in the curative setting. Some reports suggest giredestrant may reduce the risk of breast cancer recurrence or death, though specific details and outcomes are not universally reported.